This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Valoctocogene Roxaparvovec for Severe Haemophilia A

< Back

Valoctocogene Roxaparvovec for Severe Haemophilia A


Haematology and Blood Products

April 2020

Valoctocogene roxaparvovec is in development for the treatment of adult with severe haemophilia A. Haemophilia A is a rare bleeding disorder, whereby the blood does not clot properly due to the lack of or dysfunction of factor VIII clotting protein. In severe haemophilia A, this causes frequent spontaneous bleeding, including in muscles and joints. The inability of their blood to clot means that patients are at high risk of internal bleeding, including from the brain, increasing their mortality risk.

Valoctocogene roxaparvovec is a gene therapy; it can modify the genes (functional units of heredity) of individuals with haemophilia A so that they can produce the clotting protein needed to allow the blood to clot. If licensed, valoctocogene roxaparvovec would be the first gene therapy for severe haemophilia A. Valoctocogene roxaparvovec administered as a single treatment would be sufficient to maintain normal levels of factor VIII in adult males with severe haemophilia A, and might reduce the need for regular factor VIII prophylaxis (preventative treatment).

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts